Simulations Plus Agrees to $375 Million Acquisition by Altaris, Signaling New Chapter in AI-Driven Drug Development Simulations Plus, Inc., a recognized leader in model-informed drug development and artificial intelligence-enabled pharmaceutical research solutions, has entered into a definitive agreement to be…
Cellares Secures Additional $50 Million Investment, Expanding Series D Financing to $327 Million to Accelerate Global Cell Therapy Manufacturing Network Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO) dedicated to advancing automated cell therapy production, has announced a…
ARK Invest Led by Cathie Wood Joins Cellares’ $277 Million Series D Funding Round Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), has announced a new strategic investment from ARK Invest as part of its Series D financing…
Rallybio and Avenzo Therapeutics Announce Merger Backed by $215 Million Financing to Advance Next-Generation Oncology Pipeline Rallybio Corporation and Avenzo Therapeutics have entered into a definitive merger agreement that will create a publicly traded oncology-focused biotechnology company with a portfolio…
Teleflex Launches $500 Million Senior Notes Offering to Support Debt Refinancing Strategy Teleflex Incorporated has announced the launch of a private offering of $500 million in aggregate principal amount of senior notes due in 2032, marking an important step in…
LIB Therapeutics Highlights New Clinical Findings on LEROCHOL Presented at the 2026 European Atherosclerosis Society Congress in Athens LIB Therapeutics has reported new long-term clinical data for LEROCHOL® (lerodalcibep-liga), its recently approved third-generation PCSK9 inhibitor, during presentations at the European…
Gossamer Bio Reports Q1 2026 Financial Results and Highlights Recent Business Progress Gossamer Bio has reported its financial results for the first quarter ended March 31, 2026, while also providing a major business update centered on the continued advancement of…
Lantern Pharma Reports First Quarter 2026 Results While Expanding AI-Driven Oncology and Commercial AI Platform Strategy Lantern Pharma reported operational highlights and financial results for the first quarter ended March 31, 2026, outlining continued progress across its precision oncology pipeline,…
Enveric Biosciences Reports First Quarter 2026 Results and Advances Non-Hallucinogenic Neuroplastogen Pipeline Enveric Biosciences reported financial results for the first quarter ended March 31, 2026, while also providing an extensive business update highlighting continued progress in the development of its…
Sensei Biotherapeutics Advances PIKTOR Oncology Program Following Faeth Acquisition and $200 Million Financing Sensei Biotherapeutics reported its financial results for the first quarter ended March 31, 2026, while also outlining major strategic and clinical developments that the company believes will…
Adicet Bio Announces First Quarter 2026 Financial Results and Corporate Progress Updates Adicet Bio has reported financial results and operational progress for the first quarter ended March 31, 2026, highlighting continued advancement across its pipeline of allogeneic gamma delta T…
Travere Therapeutics Unveils Planned Convertible Senior Notes Offering to Refinance Existing 2029 Notes Travere Therapeutics (Nasdaq: TVTX) has announced plans to initiate an underwritten public offering of $400 million in aggregate principal amount of convertible senior notes due 2032. The…